The study of the feasibility of segmental bone defect repair with tissue- engineered bone membrane: a qualitative observation by unknown
ORIGINAL ARTICLE
The study of the feasibility of segmental bone defect repair
with tissue- engineered bone membrane: a qualitative observation
Lin Zhao Æ Jun-Li Zhao Æ Lin Wan Æ
Shuan-Ke Wang
Received: 20 July 2007 / Accepted: 19 February 2008 / Published online: 12 April 2008
 Springer-Verlag 2008
Abstract The objective of the study was to investigate
the feasibility of intramembranous osteogenesis from
tissue-engineered bone membrane in vivo. Bone marrow
mesenchymal stem cells (MSCs) of rabbits were harvested,
expanded and some of them were induced into osteoblasts.
Porcine small intestinal submucosa (SIS) was converted by
a series of physical and chemical procedures into a scaf-
fold. MSCs and induced osteoblasts were seeded separately
onto the scaffold, thus fabricating two kinds of tissue-
engineered bone membrane. A total of 12 New Zealand
rabbits were subjected to a surgical operation; a 15 mm
bone segment, including the periosteum, was resected from
the radius on both sides of each rabbit to create critical
bone defects. The two kinds of tissue-engineered bone
membrane and SIS (as control) were implanted randomly
into the site of bone defect. The animals had radiographs
and were killed after 4 weeks. The specimens were
harvested and histological examination performed for
evidence of osteogenesis. Bone tissue had formed in
defects treated by the two kinds of tissue-engineered bone
membrane at 4 weeks. This was supported by the X-ray
and histological examination, which confirmed the seg-
mental gap bridged by bone. There was no attempt to
bridge in the bone defect treated by SIS. Tissue-engineered
bone membrane, constructed by seeding allogeneic cells on
an xenogeneic and bio-derived scaffold, can repair critical
bone defects successfully.
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Introduction
Although bone possesses the capacity for regenerative
growth and remodelling, both processes become impaired
in clinical situations in which excessive bone loss is caused
by disease, trauma or through tumour resection [1]. In
order to address the need of an increasing number of
patients who require bone for skeletal reconstruction, sur-
geons can overcome the disadvantages linked to auto- or
allografts by choosing the tissue engineering approach
[2, 3]. Tissue engineering for bone faces the challenge of
exporting successful laboratory protocols; the transfer of
such technology for widespread clinical use is still
impractical.
Traditional research in bone tissue engineering describes
the use of autogenous cells as the seeding cells because of
concerns over immunogenicity [4, 5]. This is impractical
for extensive clinical application as it confines the tissue
engineering process to an individual therapy and thereby
restricts the possible future industrialization and standard-
ization of tissue-engineered products. In addition, an
individualized procedure starting with the proliferation and
construction of autogenous cells in vitro would be difficult
to satisfy the needs of tissue in emergency clinical
situations.
Bio-derived materials and synthetic polymers made into
3-D porous structures possess some rigidity and have
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served as scaffolds in most traditional bone tissue engi-
neering experiments [6–10]. However, these synthetic
derivatives do not mimic a structure similar to bone tissue
in vivo. These 3-D porous scaffolds are difficult to seed
cells beyond the outer surface, especially when present in
large volume composites. Furthermore, the superficially
seeded cells survive only through nutritional diffusion and
in so doing there is a limit to the engineered bone tissue
arising from these scaffolds of about less than 0.5 mm
thick [11], which is not of much value for clinical practice
[12]. Therefore, these large 3-D scaffolds become a spatial
hindrance for bone regeneration.
Natural bone tissue is highly vascularized and relies on
blood vessels to deliver nutrients and oxygen to cells deep
in the mineralized bone matrix. One of the greatest chal-
lenges faced in bone tissue engineering is how to enhance
the supporting scaffold and newly formed bone tissue into
establishing a natural capillary network [13]. The success
of regenerating large volumes of bone, which is valuable
for clinical use, depends on vascularization of these grafts.
This still remains the greatest challenge for tissue engi-
neering of bone, the ability to revascularize the graft.
The bone develops through two methods of osteogene-
sis: endochondral and intramembranous. Intramembranous
osteogenesis has been shown to be important in bone
fracture healing and bone defect repairing. Although there
are many successful studies of bone defect repair through
autogeneic periosteum transplantation [14–16], there are
only a few reports on the bridging of bone defects by tis-
sue-engineered bone membrane [17]. A tissue-engineered
bone membrane may potentially regenerate a large segment
bone through the intramembranous route and this would
circumvent the problem of inducing a new vascular system,
as this form of osteogenesis induces simultaneous new
bone formation and angiogenesis.
Of the several kinds of osteogenic cells, bone marrow
mesenchymal stem cells (MSCs) seem to be the optimal
seeding cells for bone tissue engineering owing to their
ease of isolation, capacity of high replication and osteo-
blast differentiation [18–20]. Recent studies have reported
that MSCs have the potential of allogeneic implantation as
these cells do not express the molecules of MHC (major
histocompatibility complex) and can adjust to the immune
system of the recipient [18, 21–24]. Therefore, selection of
MSCs as seeding cells in the construction of tissue-engi-
neered bone membrane would appear a suitable choice,
especially if the graft was used in an allogeneic recipient.
Porcine small intestinal submucosa (SIS) is a bio-
derived material, which has been shown to have low
immunogenicity in more than 1,000 inter-species implan-
tations [25]. It is also reported that SIS can enhance
angiogenesis through releasing vascular endothelial growth
factor (VEGF) during biodegradation in vivo [26]. There
are several structural characteristics in SIS that are similar
to periosteum, which make it optimal for use as a scaffold
in tissue-engineered bone membrane viz., its elastic tex-
ture, biodegradability and thinness [26, 27]. The membrane
structure provides a large area for cells to attach and could
permit cell survival through nutritional diffusion in the
early stages before intrinsic angiogenesis. In addition, the
membrane can guide the process of bone regeneration
[28, 29].
Materials and methods
Porcine small intestinal submucosa (SIS) was harvested
from the small intestine of healthy pigs within 4 h after
killing. The procedure of processing SIS was in accordance
with published protocols [26–28]. The submucosa layer
was detached from the serous coat and muscular layers by
blunt dissection and then cleaned by washing continuously
with 40C water. This submucosa layer was then treated
with a series of chemical procedures at room temperature
with the volume ratio between the submucosa matrix and
liquid used below being 1:100 (v/vt). The submucous
membrane was submerged in 100 mmol/L EDTA and
10 mmol/L NaOH (pH11–12) for 16 h; deionized water
was used to rinse until clear. The membrane was then
soaked in a mixture of 1 mmol/L HCl and 1 mmol/L NaCl
(pH 0–1) for 6*8 h. Rinsing with deionized water was
repeated and subsequent immersion was in 1 mmol/L NaCl
dissolved with PBS for 16 h, followed by rinsing with
deionized water. It was then dipped into PBS (pH 7–7.4)
for 2 h and further rinsed with deionized water for 2 h (pH
5.8–7.0). The submucous membrane was then soaked into
0.1% peroxyacetic acid and 20% ethanol for 8 h, rinsed
with 0.05% sodium azide (Sigma) dissolved with PBS for
2 h and freeze dried under -70C with lyophilize r(HETO-
HOL Power Dry LL3000) for more than 8 h. It was then
packaged in a plastic cover and irradiated (25–35 kGy)
under Co60 c-ray for half an hour. The SIS products were
stored in a -80C refrigerator for later use.
Isolation, cultivation and osteogenic differentiation
and identification of rabbit-derived MSCs
Bone marrow aspirates were harvested in heparin (200 U/mL
total) from the femoral medullary canal of healthy neonatal
(less than 10 days old) New Zealand rabbits. The cell
culture was processed according to a modified protocol
[5, 6]. The aspirates were mixed with equal volumes of
Dulbecco’s Modified Eagles Medium (DMEM, Gibco)
supplemented with 10% fetal bovine serum (FBS, Gibco)
and centrifuged at 1,000 rpm for 10 min. The fat layer and
supernatant were removed. The recovered cells were
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re-suspended in 5 mL DMEM containing 10% FBS and
layered over with Percoll (Pharmacia) at a density of
1.073 g/L and then centrifuged at 3,000 rpm for 30 min.
The middle layer of granules were removed carefully and
washed with PBS at 1,000 rpm centrifugation twice for
5 min and finally re-suspended in DMEM supplemented
with 10% FBS, penicillin G (100 U/mL) and streptomycin
sulphate (100 mcg/mL). Cellular cultures were started at a
cellular concentration of 2 9 105/mL in 25 cm2 flasks and
maintained at 37C in a humidified 5% carbon dioxide
environment. When the cultures reached 90% of conflu-
ence, the cells were passaged. On passaging, the cells were
detached from the flask by incubation with a mixture of an
enzyme solution of 0.125% trypsin(Gibco) and 0.02%
ethylenediaminetetraacetic acid (EDTA, Gibco) for
2–5 min at room temperature.
Part of the MSCs from passage 3 were stimulated for
1 week in a standard medium supplemented with 50 mg/L
ascorbic acid (Sigma), 10 mmol/L b-glycerophosphate
(Sigma) and 10-8 mol/L dexamethasone (Sigma).
Induced MSCs were harvested with the mixture of
enzymes mentioned above and transferred to sterile slides
for cellular adherence. The cells on the slides were fixed
for more than 72 h with 4% paraformaldehyde or cool
acetone at 4C, respectively. The former was used as a
specimen for immunocytochemistry and the latter for
alkaline phosphatise (ALP) detection. The specimens for
immunocytochemistry were stained using osteocalcin and
a collagen type I immunohistochemistry detection kit
(Boster, Wuhan, China) according to routine procedures;
ALP detection was carried out using ALP’s Gomori
staining.
Preparation of implants
To construct bone membrane implants, we choose MSCs
and osteoblasts induced from the MSCs described above
as the osteogenetic seeding cells. These two types of
seeding cells were combined with SIS, which ubiquitously
served as the prefabricated scaffold, thereby producing
two kinds of tissue-engineered bone membrane: namely,
tissue-engineered bone membrane (M1) constructed by
MSCs and SIS, and tissue-engineered bone membrane
(M2 ) constructed by osteoblasts (induced from MSCs)
and SIS. The procedure of combining seeding cells and
the scaffold will be described briefly. First, the SIS was
clipped into a size of 2 cm 9 2 cm and spread on the
bottom of wells of a 6-well plaque and sterilized again
under ultraviolet for more than an hour before being
immersed overnight into DMEM containing 20% FBS.
The seeding cells were detached from the culture flasks
with co-enzymes and the cellular concentration adjusted
to 2 9 106/mL with DMEM containing 10% FBS. A
200 lL cellular suspension was applied onto the surface
of the scaffold in each well. The culture of cells and
scaffold were gently agitated in the incubator and left for
6 h until more culture medium was added. The incubation
period lasted for 7 days before in vivo implantation was
performed.
Scanning electron microscopy (SEM)
Some of the tissue-engineered bone membrane implants,
which were cultured for 5 days were removed from the
6-well plaque and washed twice with PBS before being fixed
with 2.5% neutral glutaraldehyde for scanning electron
microscopy (SEM JSW-680LA, Japan) inspection. The
surface of these implants was checked by SEM to ensure that
the seeding cells adhered onto the scaffold abundantly.
Animals and operative procedures
Twelve 2-month-old New Zealand rabbits, 2.0–3.0 kg in
weight, and purchased from the Animal Experiment Centre
of the Lanzhou Institute of Biological Products (Lanzhou
city, Gansu province, China) and approved by the Asso-
ciate of Experiment Animal of Gansu Province were used
in the study. All experiments were conducted with strict
observation of institutional guidelines for the care and use
of laboratory animals.
The rabbits were anaesthetized with an intraperitoneal
injection of 3% pentobarbital solution (40 mg/kg body
weight) before surgery. Under sterile conditions, both sides
of the mid-shaft of the radius was exposed through a lateral
longitudinal skin incision and the forearm muscles divided.
A 1.5 cm long section of the diaphysis was removed
together with the periosteum using a cutting saw, thereby
creating a segmental bone defect. The animals were then
divided randomly into three groups:
1. group A - defect covered with M1;
2. group B - defect covered with M2 and
3. group C - defect covered with SIS.
All the prepared implants were wrapped snug around the
ends of the bone defect and the edges of the bone
membrane sutured with a 7-0 atraumatic suture. This
converted the flat implant into a tubular membrane, which
bridged across the ends of the bone defect. The incision
was closed with 1-0 nylon suture. The forearms of the
rabbits were immobilized with external fixators; antibiotics
were injected routinely for the first 5 days post-surgery.
The animals were reared separately for 4 weeks. All
animals were killed by aeroembolism through intravenous
air injection at 4 weeks and the specimens in the middle
area of the defect were excised for histological
examination.




All animals were radiographed (DR3000 Dryview8900,
Koda, Japan) at 4 weeks after the external fixators were
removed. The anteroposterior views of the radius and ulna
from both sides of each animal were obtained by X-ray and
the bone formation evaluated.
Histological examination
For histological examination, samples were fixed with 4%
paraformaldehyde in a 0.1 M phosphate buffer (pH 7.4) for
3 days. Following fixation, the samples were decalcified
with 10% EDTA-2Na solution for 4 weeks at 4C. After
demineralisation, the specimens were dehydrated through
an ascending ethanol series and mounted in paraffin.
Sections 5 lm thick were obtained and stained with
haematoxylin-eosin and Masson to observe new bone
formation under microscopy.
Results
Cell and scaffold and implant
The MSCs we cultured showed a uniform fibroblast-like
appearance as well as high proliferating potential (Fig. 1).
The cellular components resembled the stem cells descri-
bed in the literature. Although 1 week of osteogenic
induction cannot change the MSCs into a typical osteoblast
appearance, the induced MSCs did show some osteogenic
differentiation phenotype with a high expression of ALP,
collagen type I and osteocalcin content intracellularly
(Fig. 2). These findings suggested that the MSCs had
already differentiated into osteoblasts functionally.
The SIS scaffold we manufactured was a white coloured
membrane-like structure with a 100 ± 20 lm thickness
and a flexible texture similar to natural bone membrane
(Fig. 3). SEM observation revealed that the SIS had a
velvet-like surface and irregular porous membrane struc-
ture constituted by mesh-like collagen fibre bundles
(Fig. 4). The characteristics (thickness and porosity) of SIS
were such that it was feasible to fabricate a tissue-engi-
neered bone membrane implant. This scaffold not only
provided a large cellular adherence area but also had the
potential to allow the seeded cells to survive through dif-
fusion of the nutrients from outside the scaffold owing to a
thickness of less than 0.5 mm [11]. SEM observation of the
surface of the tissue-engineered bone membrane showed
that the seeded cells adhered to the SIS extensively with
almost all of the scaffold surface occupied (Fig. 5).
X-ray evaluation
All defects were clearly discernible with no bone formation
observed after 4 weeks at sites treated only with SIS
(Fig. 6). This contrasts with the radio-opaque tissue
observed at the same time at all sites treated with the M1 or
M2 samples. The observed new bone density was lower
than that at the edges of the defect and of cortical bone but
higher than that of the olecranon process and medullary
cavity. The defect treated with M1 or M2 were almost
completely bridged and occupied by a newly formed,
uniform density callous. Neither hypertrophy nor atrophy
was observed on both ends of the bone defect.
Histological observation
Histological sections showed fibrous connective tissue and
SIS degraded remnants filling in the region of defect
repaired with SIS alone with no discernable osseous tissue.
In comparison, newly formed osseous tissue was detected
in the defect region treated with M1 or M2. The new bone
tissue grew around irregular spherical porosities, which
were occupied partially by medullary cavities or vessels in
addition to degraded remnants of SIS (Fig. 7). No inflam-
matory cells were identified in all sections from all groups.
Discussion
The aim of this work was to investigate whether a biomi-
metic periosteum, namely tissue-engineered bone
membrane composites constructed in vitro, could form
bone tissue in the allogenic rabbit.
Fig. 1 Cultured rabbit MSCs showed a classical, long fusiform shape
and a high proliferating potential that caused them to easily undergo
confluence
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Although the seeding cells (MSCs or osteoblasts
induced from MSCs) were allogenic, this study succeeded
in forming new bone tissue without immunological
rejection (as determined by histological examination). It
was reported that MSCs have a highly reduced
immunoreactivity in allogenic transfer [22–24] and the
results of this study confirm this again. In addition, it was
shown that whilst the MSCs can survive and form bone
tissue in an allogenic environment, the osteoblasts induced
from MSCs still maintain the low-immunogenicity char-
acter of parent MSCs. This result holds potential for
manufacturing tissue-engineered implants using allogenic
bone marrow mesenchymal stem cells, which are free from
immunological rejection. It also suggests that mature
cellular lineages induced from these MSCs will have a low
immunogenicity and opens the way for studying allogenic
somatic mature cells transfers, an area which has always
been impractical owing to the barrier of immunological
rejection.
Fig. 2 MSCs induced for 7 days with a mixture of osteogenetic
inducer of 50 mg/L ascorbic acid, 10 mmol/L b-glycerophosphate
and 10-8 mol/L dexamethasone. Athough there was no obvious
morphological change, microscopically, they already showed osteo-
genic differentiation. a Induced MSCs expressed large quantities of
ALP intracellularly (ALP Gomori staining, 9100). b, c show
osteocalcin and I-collagen expression, respectively, confirmed by
immunocytochemistry (ABC 9100). All of these three phenotypes
proved that the MSCs had differentiated into osteoblast
Fig. 3 Macroscopical view of scaffold (SIS straps sealed in a sterile
plastic bag). Manufactured SIS is a white membrane-like biomate-
rial,100 ± 20 lm in thickness, and the texture is just as flexible as
natural bone membrane. This biomaterial was also easy to handle for
clipping, sterile radiation and sealing preservation
Fig. 4 SEM picture of the surface of SIS. Manufactured SIS show a
velvet-like, broad surface with numerous fibre bundles, which form a
variety of small, irregular porosities
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Successful new bone formation, without evidence of
immunological rejection, was also attributed to the SIS,
which, despite being derived from a xenogeneous animal,
has a low xenogeneic immunoreactivity, in accordance
with published literature [25].
Two of the greatest challenges faced in bone tissue
engineering is how to provide nutrition to the seeded cells
in the early stages before the formation of new vessels and
how to induce a natural capillary system into the implant
composite later [13]. The thickness (100 ± 20 lm) of SIS
can permit attached cells to survive early on through dif-
fusion of nutrients from the interstitial fluid. The
biodegraded leftovers of SIS may contribute to the for-
mation of vascular tissues; it was noted in this study that
the leftovers of SIS were accompanied with neovascules in
cavities within the newly formed bone tissue. This suggests
that SIS degradation is relevant to angiogenesis and the
mechanism is thought to be linked to large amounts
of vascular epithelial growth factor (VEGF) in the SIS
[26–28].
Successful bone formation was observed in regions
where the fragmental bone defect was treated with tissue-
engineered bone membrane constructed of either allogenic
MSCs or with osteoblasts induced from allogenic MSCs. It
is not possible, within the constraints of this study, to report
on the relative efficacies of the different seeding cells in
repairing bone defects, but the osteogenetic potential of
allogenic tissue-engineered bone membrane in animals
forms the basis for further study. The technique of bone
regeneration through tissue engineering in this study is
quite different from traditional ones, which have attempted
to regenerate bone directly by constructing a 3-D implant
[6–10]. This study has used a novel method of experi-
mental bone formation (intramembranous osteogenesis) in
a defect. Our results have asserted that the bone defect,
even when large, may be repaired by tissue-engineered
bone membrane efficiently because of naturally induced
angiogenesis. The materials of this tissue-engineered
composite, which are derived from the allogenic and the
xenogenic sources are cheap and abundant and, therefore,
may be much more practical for widespread clinical use.
This pilot qualitative study was conducted to observe the
feasibility of an innovative scheme in bone tissue engi-
neering. Although this has shown successful bone defect
repair and offered a promising protocol to regenerate bone
tissue, there are still several issues unanswered: for
instance, the mechanism of immunogenicity against allo-
genic cells and xenogenic biomaterials; the long-term
Fig. 5 SEM picture of tissue-engineered bone membrane after
5 days. The seeding cells adhered to the surface of SIS abundantly
Fig. 6 Representative rabbit radial radiographs, 4 weeks after the
implantation operation (red line shows the region of radial bone
defect). a The segmental bone defect treated with tissue-engineered
bone membrane M1(MSC + SIS) showed bone repairing. b The
critical size bone defect treated with tissue-engineered bone mem-
brane M2 (osteoblast induced from MSC + SIS) also showed bone
repairing. c The segmental bone defect treated with SIS is empty
under X-ray detection. These radiographs confirmed that critical bone
defect can be repaired by tissue-engineered bone membrane, either
constructed with seeding cells of allogenic MSCs or osteogenetic
induced allogenic MSCs
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behaviour of tissue-engineered bone; and quantitative
aspects of this mechanism.
Conclusion
1. Tissue-engineered bone membrane, constructed by
allogeneic seeding cells and xenogeneic bioderived
materials, has osteogenetic potential and can repair
fragmental bone defects successfully.
2. MSCs and osteoblasts induced from MSCs maintain a
low immunogenicity in vivo within tissue from an
allogenic animal.
3. SIS used as a scaffold is an ideal biomaterial for
constructing tissue-engineered bone membrane
because of its low immunogenicity and thin porous
membrane structure.
4. Seeding cells attached on a thin membrane scaffold
can survive because of the diffusion of nutrients from
the interstitial fluid.
5. A vascular system can establish naturally in new bone
tissue derived from tissue-engineered bone membrane.
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